This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
Glenmark said it along with its US-based partner has got the US health regulator's nod to manufacture and market two oxycodone products, used for treating moderate to severe pain, in the American market. The company's US arm, Glenmark Generics Inc and Lehigh Valley Technologies (LVT) have received US Food and Drug Administration nod for Oxycodone immediate release capsules, the company said in a filing to the Bombay Stock Exchange.
As drug multinationals from the United States demand a stronger intellectual property regime that gives exclusive marketing rights for their patented medicines in India, their own government has said the IP system is partly responsible for the extraordinary increase in prices for some medicines in the US.
The Valcyte case is vital as it bars incremental innovation and recognises the right of patient groups to oppose patents.
US-based Purdue Pharma has filed a patent infringement suit against India's largest drug company, Ranbaxy, after the latter's wholly-owned US subsidiary, Ranbaxy Pharmaceuticals Inc, applied for marketing approval of a low-cost version of Purdue's pain relieving medicine, Oxycodone.
Investors indulged in profit booking at attractive and higher valuations
In a statement on Tuesday, the European Commission said it had requested 'information from certain pharma companies asking them to submit copies of their patent settlement pacts.'
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
The comments need to be submitted to the Competition Commission of India within 15 days, along with supporting documents on how the merger can adversely impact the concerned person or entity, the regulator said, while adding that it would not consider 'unsubstantiated objections' to the deal.
Delegation visit ahead of patent law report.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
The long-pending issue of seizure of Indian generic drugs by European Union countries has been resolved, with the EU accepting India's position and agreeing to amend the rules to plug the loopholes that led to the seizure of shipments.
GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.
Joaquin Phoneix (Joker) and Renne Zellweger (Judy) should keep their fingers crossed, says Kumar Abishek.
Revival in domestic business should also help overall revenue growth.
As the death toll in the country from coronavirus jumped by a record 445 to 13,699, the Centre maintained that the number of infections per lakh population was among the lowest in the world. The new cases surged by over 10,000 for the 11th day in a row and rose by 14,821 to take the total to 4,25,282, according to health ministry data.
Drug maker Dr Reddy's Laboratories on Wednesday said it was looking out for partnerships to expand its presence in Japan.
Swiss drug multinational Roche AG suffered yet another setback in its ongoing patent fights in India after the Chennai patent office rejected its claim over Valcyte (valganciclovir).
A senior European Union representative said here on Tuesday that the body would soon change its Customs laws to address the issue of seizures of Indian generic drug shipments while en route for export to other countries.
Pharma major Wockhardt on Wednesday said it has launched Tamsulosin capsules, indicated for problem of prostate enlargement, in the US market on the day one of the expiry of patent covering the drug.
Both companies can now complete the deal.
Pharma major Dr Reddys Laboratories has voluntarily recalled 78,876 bottles of 2mg and 4mg Risperidone, generic version of Resperdal, tablets in the United States.
The year also witnessed Mumbai-based Sun Pharmaceutical continue the tussle for taking over Israeli drug firm Taro, while MNCs struck alliances with Indian companies to capitalise on generics expertise in New Delhi.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
Opportunities will also stem from the clear support for generics.
The central government's decision to stockpile another 20 million capsules of generic Tamiflu (Oseltamivir) to strengthen its preparedness to fight the H1N1 epidemic has alerted domestic pharmaceutical companies.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
India and the European Union (EU) have begun discussions to resolve the ongoing dispute over the seizure of Indian generic drugs consignments in transit at European ports. Lutz Guellner, spokesperson for the European Trade Commissioner, told Business Standard that a meeting of the EU-India Joint Customs Cooperation Committee held in New Delhi on Thursday proved "constructive" with an "open discussion of the issues" taking place.
Plans to set up an integrated pharma firm in a phased manner.
Dr Reddy's Laboratories received a major setback in the US, as a court there granted a motion seeking a preliminary injunction to block the launch of its generic version of Sanofi-Aventis' anti-allergic drug, Allegra D24.
Early SUVs were descendants from commercial and military vehicles such as the World War II Jeep and Land Rover.
This increase is despite the decreased growth of drug sales in the US - the world's largest market - which has seen a tightening of regulations and aggressive competition.
Unlike the 2012 manifesto, the BJP has chosen not to make any extravagant promises.
The future looks somewhat bright for the Indian pharmaceutical industry which is wholly into generics. It expects to get a push from the new US legislation bringing into the health-care fold 32 million or 10 per cent of the country's population which is currently uninsured.
US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.
Gone Kesh is a good-natured coming-of-age tale, applauds Sukanya Verma.
The Department of Pharmaceuticals has submitted a freight subsidy scheme for exporters to the Commerce Ministry so that they could take alternate routes and avoid transit through Europe, which is a shorter route with better connectivity.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
We don't expect any big changes in on excise duty and custom duty rates, except in life saving drugs.
'Taking serious note of the action by unscrupulous elements to malign the Indian generic pharma industry, the embassy of India, Beijing, has been requested to lodge a strong protest with concerned Chinese authorities and also to impress upon them to take stringent action against such unscrupulous elements,' a commerce ministry statement said in New Delhi.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances